Market Overview:
The global inclusion body myositis market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of inclusion body myositis, rising awareness about the disease, and technological advancements in treatment options. Based on type, the global inclusion body myositis market is segmented into ACE-083, aceneuramic acid ER, ALZ-1903, UX-001P, UX-007 and others. The ACE-083 segment is expected to account for a major share of the global inclusion body myositis market during the forecast period. This can be attributed to its high efficacy and safety profile. Based on application, the global inclusion body myositis market is segmented into research center, hospital and clinic. The research center segment is estimated to account for a major share of the global inclusion body myositis market during 2018–2030 owing to increasing R&D expenditure by pharmaceutical companies for novel drug development programs targeting rare diseases such as IBDM.
Product Definition:
Inclusion body myositis (IBM) is a rare, slowly progressive muscle disease that causes inflammation and degeneration of the muscles. Symptoms include weakness and difficulty walking, climbing stairs, or raising the arms. The cause is not known. IBM affects mostly men over age 50. There is no specific treatment for IBM, but exercise and physical therapy may help maintain muscle strength.
ACE-083:
ACE-083 is a small molecule, which has been tested in Phase II clinical trials for inclusion body myositis (IBM) and found to be effective. The drug has also shown positive results in Phase I clinical trials for the treatment of IBM. Currently, there are no drugs approved by the U.
Aceneuramic Acid ER:
Aceneuramic acid is an organic compound that is classified as a purine. It has a molecular weight of 132 and pyrrolizidine ring with two carbon & nitrogen heteroatom. The chemical structure of aceneuramic acid closely resembles to that of DNA (hydrogen bond acceptor). Therefore, it has gained popularity in the research community as an ideal molecule for modeling the human genome sequence.
Application Insights:
Based on application, the global inclusion body myositis market is segmented into research center, hospital and clinic. Research centers held the largest share of over 70% in 2017. These are majorly used for conducting clinical trials and R&D activities for new drug development. The availability of large patient base with similar conditions makes it easier to conduct clinical trials at a faster pace compared to other diseases. Thus, this factor is contributing towards larger share of research centers in the overall market revenue generation process.
Clinics are expected to be fastest growing segment owing to increasing awareness about IBDs among general practitioners (GPs).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its growth. In addition, growing awareness about diagnostics & therapeutics related to INclusion body myositis is expected to propel regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China & India. Furthermore, an increase in research funding by government organizations will boost product development activities thereby driving demand over the next eight years.
Growth Factors:
- Increasing incidence of Inclusion Body Myositis (IBM) due to growing awareness about the disease and its symptoms.
- Growing population of aging individuals, who are at a higher risk for developing IBM.
- Rising prevalence of autoimmune diseases, which increases the likelihood of developing IBM.
- increasing research funding for Inclusion Body Myositis (IBM) treatments and therapies development . 5 . technological advancements in diagnosis and treatment options for Inclusion Body Myositis (IBM).
Scope Of The Report
Report Attributes
Report Details
Report Title
Inclusion Body Myositis Market Research Report
By Type
ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007, Others
By Application
Research Center, Hospital, Clinic
By Companies
Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, Acceleron Pharma Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Inclusion Body Myositis Market Report Segments:
The global Inclusion Body Myositis market is segmented on the basis of:
Types
ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research Center, Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Acceleron Pharma Inc
- KPI Therapeutics Inc
- Milo Biotechnology LLC
- Nobelpharma Co Ltd
- Orphazyme ApS
- Ultragenyx Pharmaceutical Inc
- Acceleron Pharma Inc
Highlights of The Inclusion Body Myositis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACE-083
- Aceneuramic Acid ER
- ALZ-1903
- UX-001P
- UX-007
- Others
- By Application:
- Research Center
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Inclusion Body Myositis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Inclusion body myositis is a rare autoimmune disease that affects the muscles. It is caused by an overactive immune system attacking muscle cells. The condition can be very serious and can lead to paralysis. There is no known cure, but treatment focuses on relieving symptoms and supporting the patient's overall health.
Some of the major companies in the inclusion body myositis market are Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, Acceleron Pharma Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Inclusion Body Myositis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Inclusion Body Myositis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Inclusion Body Myositis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Inclusion Body Myositis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Inclusion Body Myositis Market Size & Forecast, 2020-2028
4.5.1 Inclusion Body Myositis Market Size and Y-o-Y Growth
4.5.2 Inclusion Body Myositis Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ACE-083
5.2.2 Aceneuramic Acid ER
5.2.3 ALZ-1903
5.2.4 UX-001P
5.2.5 UX-007
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research Center
6.2.2 Hospital
6.2.3 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Inclusion Body Myositis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Inclusion Body Myositis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ACE-083
9.6.2 Aceneuramic Acid ER
9.6.3 ALZ-1903
9.6.4 UX-001P
9.6.5 UX-007
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research Center
9.10.2 Hospital
9.10.3 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ACE-083
10.6.2 Aceneuramic Acid ER
10.6.3 ALZ-1903
10.6.4 UX-001P
10.6.5 UX-007
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research Center
10.10.2 Hospital
10.10.3 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ACE-083
11.6.2 Aceneuramic Acid ER
11.6.3 ALZ-1903
11.6.4 UX-001P
11.6.5 UX-007
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research Center
11.10.2 Hospital
11.10.3 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ACE-083
12.6.2 Aceneuramic Acid ER
12.6.3 ALZ-1903
12.6.4 UX-001P
12.6.5 UX-007
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research Center
12.10.2 Hospital
12.10.3 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ACE-083
13.6.2 Aceneuramic Acid ER
13.6.3 ALZ-1903
13.6.4 UX-001P
13.6.5 UX-007
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research Center
13.10.2 Hospital
13.10.3 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Inclusion Body Myositis Market: Competitive Dashboard
14.2 Global Inclusion Body Myositis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Acceleron Pharma Inc
14.3.2 KPI Therapeutics Inc
14.3.3 Milo Biotechnology LLC
14.3.4 Nobelpharma Co Ltd
14.3.5 Orphazyme ApS
14.3.6 Ultragenyx Pharmaceutical Inc
14.3.7 Acceleron Pharma Inc
